Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

David J. Kuter(Harvard University), Janet L. Nichol(Amgen (United States)), Francis J. Cuevas(Marshall University), Adrian C. Newland(Queen Mary University of London), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Jeffrey S. Wasser(Community Cancer Center), Vinod Pullarkat(City of Hope), Roger M. Lyons(Hematology Oncology Associates), Solomon I. Hamburg(Tower Cancer Research Foundation), Ronald S. Go(Mayo Clinic), Troy H. Guthrie(Baptist Cancer Center), Lawrence Rice(Methodist Hospital), Martin R. Schipperus(Rijnland Ziekenhuis), Craig M. Kessler(Georgetown University), Robert L. Redner(UPMC Hillman Cancer Center), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Frank T. Slovick(Hematology Oncology Associates), James N. George(University of Oklahoma), Jean‐François Viallard(Université de Bordeaux), James B. Bussel(Cornell University), Howard A. Liebman(Keck Hospital of USC), Howard R. Terebelo(Michigan Cancer Research Consortium), Francis M. Senecal(Northwest Medical Specialties), Terry Gernsheimer(Bloodworks Northwest), François Lefrère(Hôpital Necker-Enfants Malades), J. Th. M. de Wolf(University Medical Center Groningen), Alan Lichtin(Cleveland Clinic), David H. Henry(Pennsylvania Hospital), Ding‐Ding Guo(Amgen (United States)), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Emmanuelle Bourgeois(Hôpital Claude Huriez), Carlos Grande(Research Institute Hospital 12 de Octubre)
The Lancet
February 1, 2008
Cited by 862


Related Papers